Literature DB >> 16219319

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

Rinpei Niwa1, Akito Natsume, Aya Uehara, Masako Wakitani, Shigeru Iida, Kazuhisa Uchida, Mitsuo Satoh, Kenya Shitara.   

Abstract

Fucose depletion from oligosaccharides of human IgG1-type antibodies results in a great enhancement of antibody-dependent cellular cytotoxicity (ADCC). The aim of this study was to clarify the effect of fucose removal on effector functions of all human IgG subclasses. A panel of anti-CD20 chimeric antibodies having a matched set of human heavy chain subclasses with different fucose contents in their oligosaccharides was constructed using wild-type and fucosyltransferase-knockout Chinese hamster ovary cells as host cells. As found previously for IgG1, fucose-negative variant of IgG2, IgG3, and IgG4 exhibited enhanced ADCC and FcgammaRIIIa binding compared with their highly fucosylated counterparts. In contrast, fucose removal did not affect complement-dependent cytotoxicity (CDC) of any IgGs. Consequently, fucose removal from IgG2 and IgG4 resulted in a unique effector function profile; they had potent ADCC and no CDC. In conclusion fucose depletion can provide a panel of IgGs with enhanced ADCC without an impact on other inherent properties specific for each IgG subclass, such as CDC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219319     DOI: 10.1016/j.jim.2005.08.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  88 in total

1.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 3.  Anti-CD30 Antibodies for Hodgkin lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

4.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

Review 5.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

Review 6.  Advances in the assessment and control of the effector functions of therapeutic antibodies.

Authors:  Xu-Rong Jiang; An Song; Svetlana Bergelson; Thomas Arroll; Bhavin Parekh; Kimberly May; Shan Chung; Robert Strouse; Anthony Mire-Sluis; Mark Schenerman
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

7.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 8.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

9.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.